N-0861 racemate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-0861 racemate
• 英文别名: N-(2-bicyclo[2.2.1]heptanyl)-9-methylpurin-6-amine
• 化学式: C₁₃H₁₇N₅
• 分子量: 243.31
• InChiKey: MTQYIGCUBBMQCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。
• PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Vidal Juan Bernat

  公开号：US20100273757A1

  公开（公告）日：2010-10-28

  The present invention provides a compound of formula (I) wherein: A represents an optionally substituted monocyclic or polycyclic aryl or heteroaryl group B represents an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 represent hydrogen or specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety selected from the moiety of formulae (IIa) and (IIb): (IIa) These compounds are useful as antagonists of the A2B receptor, for instance in the treatment of asthma.

  本发明提供了一种式为（I）的化合物，其中：A代表可选取代的单环或多环芳基或杂芳基基团；B代表可选取代的单环含氮杂芳基基团；并且要么a）R1和R2代表氢或指定的取代基，要么b）R2，R1和R1连接的—NH—基团形成从式（IIa）和（IIb）中选择的基团：（IIa）这些化合物可用作A2B受体拮抗剂，例如在哮喘治疗中。
• Method for improving learning
  申请人：St. Jude Children's Research Hospital, Inc.

  公开号：US10696972B2

  公开（公告）日：2020-06-30

  The invention is directed to a method for improving learning and/or memory (e.g., auditory, visual, somatosensory or motor) in adults and children of an age which is beyond the early critical period for learning, said method comprising inhibiting (i) ecto-5′-nucleotidase (Nt5e, aka CD73) or (ii) A1 adenosine receptor (A1R, aka Adora1) expression or function in the brain. The invention is also directed to a method for treating learning and memory defects and neurological diseases associated with an abnormal auditory, visual, or somatosensory perception by inhibiting Nt5e or A1R expression or function in the brain.

  本发明涉及一种改善成人和儿童学习和/或记忆（如听觉、视觉、体感或运动）的方法，其年龄超过了学习的早期关键期，所述方法包括抑制(i)外-5′-核苷酸酶（Nt5e，又名CD73）或(ii)A1腺苷受体（A1R，又名Adora1）在大脑中的表达或功能。本发明还涉及一种通过抑制大脑中Nt5e或A1R的表达或功能来治疗与听觉、视觉或躯体感觉异常相关的学习和记忆缺陷以及神经系统疾病的方法。
• SUBSTITUTED 9-ALKYLADENINES
  申请人：Aderis Pharmaceuticals, Inc.

  公开号：EP0778836B1

  公开（公告）日：2005-12-28
• METHODS FOR THE PREVENTION AND TREATMENT OF FIBROSIS AND SCLEROSIS
  申请人：Link Technology, Inc.

  公开号：EP1051192A2

  公开（公告）日：2000-11-15